Verrica Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9, 2023

October 25, 2023 9:33am

WEST CHESTER, PA – Oct. 25, 2023 (GLOBE NEWSWIRE) – Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, November 9, 2023, to provide a corporate update and discuss the Company’s financial results for the third quarter ended September 30, 2023.

Individuals may participate in the live call via telephone by dialing 1-877-407-4018 (domestic) or 1-201-689-8471 (international) and using the conference ID: 13741589. Participants are asked to dial in 10 minutes before the start of the call to register.

A live audio webcast of the call be accessed by visiting the investor relations section of the Company’s website,, or by clicking here. A replay of the webcast will be archived on Verrica’s website for 90 days following the event.

About Verrica Pharmaceuticals Inc. 

Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. On July 21, 2023, Verrica’s lead product, YCANTH™ (cantharidin), became the first treatment approved by the FDA to treat pediatric and adult patients with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. VP-102 is also in development to treat common warts and external genital warts, two of the largest unmet needs in medical dermatology. Verrica is developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for dermatologic oncology conditions. For more information, visit



Terry Kohler 
Chief Financial Officer

Kevin Gardner
LifeSci Advisors

Chris Calabrese
LifeSci Advisors